Not Available

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$150,000.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
N43CO201000125
Award Id:
96437
Agency Tracking Number:
N43CO201000125
Solicitation Year:
n/a
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
2143 Worth Lane, SPRINGDALE, AR, 72764-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
Y
Duns:
155516987
Principal Investigator:
Y. ANDREWWANG
(479) 236-7147
AWANG@OCEANNANOTECH.COM
Business Contact:
Research Institute:
n/a
Abstract

Quantum dots (ODs) with unique optical properties such as size-tunable emission , simultaneous excitation,  high brightness, and very slow photobleaching ¿can be used as powerful cancer diagnostic tools providing the  -"'¿cile-cular¿ profiles of cancer cases based on common clinical biopsies and allowing the tumor cell detection  ¿and-analysis in highly heterogenous samples and rare cell populations. However, researchers have found  that the¿ fluorescence intensity of QDs changes under light irradiation and the QD-antibody conjugates  detaches from tissues easily during the staining process, making it very difficult to quantify expression level  of biomarkers. To develop QD based multiplexing and quantitative kits for clinical applications, this team  proposes to increase the QD stability through the multi-shell coating strategy in Aim 1 and to develop the  high-bioaffinity QD-Antibody (Ab) through the adaptor protein strategy in Aim 2. As the first application, the  improved QO-Ab technology will be used to develop a multi-biomarker imaging kit for prediction of human  papilomavirus (HPV)- associated cancer. HPV is one of the risk factors in cancer development. Accurate  evaluation of the impact of HPV on cancer development requires incorporation of our knowledge of the  pathways by which HPV causes cancer. This team would like to use three QD-conjugated antibodies which  specifically bind to HPV-related proteins as a predictor for cancer assessment. As a preparation for the  phase II development of this technology, Aim 3 and 4 will validate Ihe HPV specific QD-Abs and oplimize Ihe  condition for multiple QD-staining and quantification, respectively, by using human cancer cell lines and  tissues.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government